Clinical spectrum, treatment, and outcome of patients with type II mixed cryoglobulinemia without evidence of hepatitis C infection

Journal of Rheumatology

Volumn 38, Issue 4, 2011, Pages 716-722

  Foessel, Laure ^a   Besancenot, Jean François ^b   Blaison, Gilles ^c   Magy Bertrand, Nadine ^d   Jaussaud, Roland ^e   Etienne, Yves ^f   Maurier, François ^g   Audia, Sylvain ^h   Martin, Thierry ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c Pasteur Hospital   (France)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f City Hospital   (France)

^g Department of Endocrinology   (France)

^h HÔPITAL DU BOCAGE   (France)

Author keywords

Cryoglobulinemia; Rheumatoid factor; Rituximab; Vasculitis

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LENALIDOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HEPATITIS; HEPATITIS C; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; MALE; NEUROPATHY; OUTCOME ASSESSMENT; PEPTIC ULCER BLEEDING; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PURPURIC RASH; PYELONEPHRITIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SEPTIC SHOCK; SEPTICEMIA; SIDE EFFECT; TYPE II MIXED CRYOGLOBULINEMIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79953328070     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100898     Document Type: Article

References (27)

1. Brouet JC, Clauvel JP, Dannnon F, Klein M, Seligmann M. Biological and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
2. Tedeschi A, Barate C, Minola E, Morra E. Cryoglobulinemia. Blood Rev 2007;21:183-200.
3. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001;31:628-38. (Pubitemid 32642895)
4. Horcajada JP, Garcia-Bengoechea M, Cilla G, Etxaniz P, Cuadrado E, Arenas JI. Mixed cryoglobulinemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes. Ann Med 1999;31:352-8. (Pubitemid 29497697)
5. Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C and liver damage. Gastroenterology 1994;106:1291-300. (Pubitemid 24129247)
6. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5.
7. Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994;84:3047-53. (Pubitemid 24328097)
8. Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573-7.
9. Cohen Tervaert JW, Van Paassen P, Damoiseaux J. Type II cryoglobulinemia is not associated with hepatitis C infection. Ann NY Acad Sci 2007;1107:251-8. (Pubitemid 47528802)
10. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000;27:2172-8.
11. Cacoub P, Ratziu V, Myers RP, Ghillani P, Piette JC, Moussalli J, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 2002;36:812-8. (Pubitemid 35177412)
12. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617-23. (Pubitemid 38401876)
13. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26. (Pubitemid 36857852)
14. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34. (Pubitemid 36857853)
15. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842-6. (Pubitemid 43985372)
16. Harris NL, Jaffe ES, Diebold J, Glandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
17. Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenof B, et al. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine 2009;88:341-8.
18. Trejo O, Ramos-Casals M, Garcia-Carrasco M, Yague J, Jimenez S, de la Red G, et al. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine 2001;80:252-62. (Pubitemid 32703064)
19. Mascia MT, Ferrari D, Campioli G, et al. Non HCV-related mixed cryoglobulinemia. Dig Liver Dis 2007;39 Suppl 1:S61-4.
20. Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006;166:2101-8. (Pubitemid 44631398)
21. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23.
22. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-7.
23. Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009;60:3848-55.
24. Cohen H, Green S, Jones S, Amos N, William BD. Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinemia. Rheumatology 2007;46:366-7. (Pubitemid 46189804)
25. Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cathebras P, et al. Safety and efficacy of rituximab in non-viral cryoglobulinemia vasculitis: Data from the French AIR registry. Arthritis Care Res 2010 Aug 25. [Epub ahead of print]
26. Zeldis JB, Knight RD, Jacques C, Tozer A, Bizzari JP. Lenalidomide in multiple myeloma: current role and future directions. Expert Opin Pharmacother 2010;11:829-42.
27. Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003;187:946-55. (Pubitemid 36337907)